Feb 5, 2026
how robust is ribociclib's data on progression-free survival compared to palbociclib and abemaciclib
’s evidence base for improving progression‑free survival (PFS) is strong and consistent: randomized phase III trials demonstrated statistically significant PFS benefit versus endocrine therapy alone, ...